KRAS and non-small cell lung carcinoma: In addition to the drugs mentioned above, several KRAS G12C inhibitors (LY3499446, GDC-6036, D-1553, JDQ443, BI 1,823,911, LY3537982, JAB-21822, YL-15293, and RMC-6291) and KRAS G12D inhibitors (KRpep-2d, KS-58, and MRTX1133) have been used in preclinical and clinical trials.76–79 Further evidence is needed for KRAS-targeted therapies as the first-line treatment of KRAS-mutant NSCLC.